Clinical Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
Trial Details
NCT Number NCT06961721
Lead Sponsor Changchun BCHT Biotechnology Co.
Collaborators: Inner Mongolia Center for Disease Control and Prevention, Center for Disease Control and Prevention, Fujian
Conditions Prevention of Herpes Zoster
Enrollment 600 participants
Start Date 2025-05
Primary Completion 2025-07 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-08